DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Pegloticase
Pegloticase
Pegloticase: a New Biologic for Treating Advanced Gout
PM179 Pegloticase (Krystexxa)
Colcrys
Pegloticase - Drugbank
Krystexxa® (Pegloticase)
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
Krystexxa (Pegloticase)
Krystexxa® (Pegloticase)
Pegloticase in Combination with Methotrexate in Patients with Uncontrolled Gout: a Multicenter, Open-Label Study (MIRROR) John K
Stembook 2018.Pdf
Krystexxa® (Pegloticase)
2020 American College of Rheumatology Guideline for the Management of Gout
Colchicine – an Established Medication with New Purpose (An Old Drug with New Purpose)
204820Orig1s000
Krystexxa® (Pegloticase)
Treatment Options for Gout by Jon Brady, Pharmd; Sarah Pupo, Pharmd; Eric Sidman, Pharmd; and Jennifer Malinowski Pharmd
Refractory Gout: an Overview of Pathogenesis and Treatment
Orphan Drug Designation List
Top View
Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: an Evidence-Based Update
129-5-1. Prior Authorization. (A) Any Medical Service May Be Placed by The
Gpi Drug Classification Report
Clinical Policy: Pegloticase (Krystexxa) Reference Number: ERX.SPMN.221 Effective Date: 01/17 Coding Implications Last Review Date: Revision Log
Gout and Osteoarthritis: What Works and What Doesn't?
Gout Guideline Supplementary Appendix 6 – Network Meta
Pegloticase (Krystexxa) Reference Number: ERX.SPA.197 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log
ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
National Medicines Information Centre
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
Krystexxa (Pegloticase)
Krystexxa (Pegloticase) NOTICE
Australian Statistics on Medicines 2009
New Developments in Gout Conflict of Interest Declaration Objectives
KRYSTEXXA Safely and Effectively
XANTHINE OXIDASE INHIBITORY ACTIVITY of Pandanus Amaryllifolius Roxb
Krystexxa® (Pegloticase)
Pegloticase (Krystexxa )
Krystexxa, INN-Pegloticase
Xanthine Oxidase Inhibitor Step Therapy with Quantity Limit
Krystexxa (Pegloticase)
Krystexxa® (Pegloticase)
Qualifying Therapeutic Discovery Project Grants
FDA Briefing Document
(12) United States Patent (10) Patent No.: US 9,023,856 B2 Roberts Et Al
Pegloticase (Krystexxa )
Evolvement of EU Regulations on Innovative Medicines’ Was Accepted for Poster Presentation at the 77Th International Pharmaceutical Federation
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
[Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
Allopurinol Failures Respond Well to Pegloticase
Antihyperuricemics Review – March 2020 Page 2 | Proprietary Information
Utah Medicaid Pharmacy and Therapeutics Committee Drug Class Review Antigout Agents
Anti-Gout Agents
Which Prophylactic Therapies Best Prevent Gout Attacks?
Krystexxa® (Pegloticase)
KRYSTEXXA® (Pegloticase) Injection for Intravenous Infusion
Annexes to the European Medicines Agency's 2012 Annual Report
ATC Code Title
Antihyperuricemics Review – February 2021 Page 2 | Proprietary Information
Why Does Hyperuricemia Not Necessarily Induce Gout?
Orphan Drug Designations and Approvals List As of 03‐01‐2016 Governs April 1, 2016